Navigation Links
Jeffrey Trotter Joins Pharmanet Development Group as Executive Vice President, Phase IV Development
Date:11/2/2009

PRINCETON, N.J., Nov. 2 /PRNewswire/ -- PharmaNet Development Group, Inc., a leading provider of clinical development services to pharmaceutical, biotechnology, generic drug and medical device companies, announced today that Jeffrey Trotter has joined the Company as Executive Vice President, Phase IV Development. In his role, he will provide leadership for the Company's Phase IV operations and its global expansion.

"We are very pleased to have Jeff Trotter join PharmaNet," commented Jeffrey P. McMullen, president and chief executive officer. "His depth of experience and pioneering approaches to patient registries, health economics and outcomes research will enable us to expand our services to clients seeking to undertake the full range of peri-approval research programs."

Mr. McMullen continued, "Phase IV services continue to be a growth opportunity for PharmaNet. I am confident we can strengthen our presence to become the definitive choice for research excellence in this critical and rapidly changing field."

As an entrepreneur, researcher, consultant and industry leader, Jeffrey Trotter has been an innovator in the evolving outcomes research community, most recently providing strategic and operational direction to pharmaceutical and device companies on the importance of 'real world' clinical research, observational studies and patient registries. Mr. Trotter was founder and president of Ovation Research Group, one of the leading independent research and consulting organizations providing health economics and outcomes research for pharmaceutical and medical device companies. Ovation became known worldwide for its industry-leading perspectives on patient registries, clinical studies fulfilling a broad continuum of needs ranging from product commercialization to safety surveillance and risk management. Having sold Ovation, Jeff joins PharmaNet Development Group from his independent consultancy, J. Trotter Research and Consulting.

About PharmaNet Development Group, Inc.

PharmaNet Development Group, Inc., a global drug development services company, provides a comprehensive range of services to the pharmaceutical, biotechnology, generic drug and medical device industries. The Company offers early and late stage consulting, Phase I clinical studies and bioanalytical analyses, and Phase II, III and IV clinical development programs. With approximately 2,300 employees and 43 facilities throughout the world, PharmaNet is a recognized leader in outsourced clinical development. For more information, please visit our website at www.pharmanet.com.

    Contact: Anne-Marie Hess
    Phone: (609) 951-6842
    Email: ahess@pharmanet.com

SOURCE PharmaNet Development Group


'/>"/>
SOURCE PharmaNet Development Group
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. University Medical Pharmaceuticals Selects Jeffrey Ten as Senior Vice President, International Sales
2. Dr. Harry Kovelman Joins Ferring Pharmaceuticals as Associate Medical Director for Orthopaedics
3. American Lung Association of California Joins Sheriffs Department to Support Influenza Vaccination In Sacramento
4. Marsha Fanucci Joins Ironwood Board of Directors
5. Dr. Mahdi B. Fawzi Joins Warner Chilcott as President, Global Research and Development
6. The Medco Foundation Joins With the Entertainment Industry Foundation to Give Health a Hand to Communities in Need
7. Dilon Diagnostics Joins Forces With Philips for Womens Health Solutions
8. Amarex Clinical Research Selects OmniComm Systems to Provide eClinical Solutions for Phase III Medical Device Study and Joins OmniComms CRO Preferred Program
9. UPCI Joins ExCell Research Study Using Stem Cells for Leukemia and Lymphoma Patients
10. Chuck Panozzo, Founder of Rock Band Styx, Joins GeoVax Labs, Inc. as an Advocate for Its HIV/AIDS Vaccine
11. BARC Central Laboratory Joins Alzheimers Association Research Roundtable
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... 2016 Research and Markets has announced ... in the USA"  report to their offering.  ,     (Logo: ... the current Positron Emission Tomography (PET) scanner and cyclotron ... market. Along with the current known number of PET ... , the report also contains a detailed breakdown of ...
(Date:5/5/2016)... 5, 2016 ... of the  "Europe Thrombocytopenia Market and ... to their offering.       ... ,The latest research Europe Thrombocytopenia Market ... provides comprehensive insights into Thrombocytopenia pipeline ...
(Date:5/4/2016)... Conn., May 4, 2016  Compass Diversified Holdings (NYSE: ... "Company"), an owner of leading middle market businesses, announced ... ended March 31, 2016. First Quarter 2016 ... and Reinvestment ("CAD" or "Cash Flow") of $13.6 million ... net loss of $15.0 million for the first quarter ...
Breaking Medicine Technology:
(Date:5/6/2016)... ... 06, 2016 , ... From May 4 to 6, EarQ and ... opportunity to learn more about Signia’s technology and the successful business and marketing techniques ... priority to see practices succeed in this highly competitive industry,” said Ed Keller, president ...
(Date:5/6/2016)... Arizona (PRWEB) , ... May 06, 2016 , ... ... moved domains to Sleepopolis.com . , Since launching in September, 2014 Sleepopolis ... research and testing areas, which now include pillows, sheets, mattress toppers, bed frames, ...
(Date:5/6/2016)... , ... May 06, 2016 , ... ... online provider of career-focused education and corporate training, and the National Military Family ... to announce Maritza Aquino as the second full-tuition scholarship recipient of 2016. ...
(Date:5/6/2016)... ... May 06, 2016 , ... RowdMap, Inc. ... Cross BlueShield and Former Principal Deputy Administrator at Centers for Medicare and Medicaid ... Steve Ondra, MD, Chief Medical Officer at Health Care Service Corporation (Blue Cross ...
(Date:5/5/2016)... ... May 05, 2016 , ... Qrono Inc. , ... a development collaboration with the Australian critical medicine company, Phebra Pty Ltd. ... , LAI medicines can offer improved therapeutic benefits over oral formulations, including better ...
Breaking Medicine News(10 mins):